630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study

MLA

Salvatore Grisanti, et al. “630 EO2401, a New Peptide Immunotherapy against Cancer, in Combination with Nivolumab, Induces a Strong and Durable Immune Response in Patients from the EOADR1–19/SPENCER Study.” Journal for ImmunoTherapy of Cancer, vol. 11, no. Suppl 1, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-SITC2023.0630.

APA

Salvatore Grisanti, Vivek Subbiah, Eric Baudin, Gedske Daugaard, Alfredo Berruti, Jennifer Martinez, Camilo Jimenez, Harm Haak, Jerome Kervevan, Lucie Aubergeon, Chloé Ventujol, Christophe Bonny, Laurent Chene, Joao Gamelas Magalhaes, CWillemien Menke-vander Houven van Oordt, Martin Fassnacht, Jaume Capdevila, Christelle de la Fouchardière, Dan Granberg, … Jean-Michel Paillarse. (2023). 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study. Journal for ImmunoTherapy of Cancer, 11(Suppl 1). https://doi.org/10.1136/jitc-2023-SITC2023.0630

Chicago

Salvatore Grisanti, Vivek Subbiah, Eric Baudin, Gedske Daugaard, Alfredo Berruti, Jennifer Martinez, Camilo Jimenez, et al. 2023. “630 EO2401, a New Peptide Immunotherapy against Cancer, in Combination with Nivolumab, Induces a Strong and Durable Immune Response in Patients from the EOADR1–19/SPENCER Study.” Journal for ImmunoTherapy of Cancer 11 (Suppl 1). doi:10.1136/jitc-2023-SITC2023.0630.